KyungDong Pharm home
Prescription Medicines

Neucapen cap.75mg

Product Category
Neuropathic pain treatment
Active Ingredients
Pregabalin
Appearance
A hard capsule with a reddish-brown cap and white body, containing white or slightly yellowish-white powder.
Reimbursement Code
648104160
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
Of 1 capsule
- Active ingredient: Pregabalin (in-house specification)----75mg
- Additives: corn starch, lactose hydrate, talc, capsule

2. Effectiveness
1. Treatment of peripheral and central neuropathic pain in adults
2. Epilepsy
Adjuvant for partial seizures with or without secondary systemic symptoms in adults
3. Treatment of fibromyalgia

3. Dosage and dosage
This drug is pregabalin, and the total daily dose is divided into two times a day and is administered orally regardless of food. Since this drug is mainly excreted by the kidneys, the dose should be adjusted for patients with reduced renal function. (Refer to section ‘5. Patients with renal dysfunction’)
1. Neuropathic pain
1) Peripheral neuropathic pain
Adults: The starting dose of this drug is 150 mg per day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose can be increased at subsequent 7-day intervals up to a maximum of 600 mg per day.
2) Central neuropathic pain
Adults: The starting dose of this drug is 150 mg per day. Based on the individual patient's response and tolerability, the dose can be increased to 300 mg per day after 1 week. After an additional week, the dose can be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to ‘4. Discontinuation of administration’)
2. Epilepsy
Adults: The starting dose of this drug is 150 mg per day. Based on the individual patient's response and tolerability, the dose can be increased to 300 mg per day after one week. If necessary, the dose can be increased at 7-day intervals up to a maximum of 600 mg per day.
3. Fibromyalgia
The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The starting dose of this drug is 75 mg twice a day (150 mg per day), and based on effectiveness and tolerability, the dose can be increased by 150 mg twice a day (300 mg per day) within one week. For patients who do not experience sufficient benefit from the dose of 300 mg per day, the dose can be increased to 225 mg twice daily (450 mg per day) within one week. Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or sufficient tolerability at this dose. Considering dose-dependent adverse reactions, administration of doses exceeding 450 mg per day is not recommended.
4. Discontinuation of administration
Based on current clinical experience, if this medicine is to be discontinued, it should be withdrawn gradually over at least one week.
5. Patients with renal dysfunction
After passing through systemic circulation, this drug is mainly excreted through the kidneys in unchanged form. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with reduced renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the formula below.

- Formula, [Table 1]. Refer to the manual -

This drug is effectively removed from plasma by hemodialysis. (About 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, additional supplementary doses should be administered immediately after hemodialysis every 4 hours.
6. Patients with liver dysfunction
No dose adjustment is necessary in patients with liver dysfunction.
7. Pediatric and adolescent patients
Because there are insufficient safety and efficacy data for children under 12 years of age and adolescents between 12 and 17 years of age, administration is not recommended.
8. Elderly (age 65 or older)
In elderly patients with reduced renal function, a dose reduction may be necessary.

4. Precautions for use
1. Warning
1) Suicidal impulse and suicidal behavior
(1) Because the risk of suicidal impulses or behavior increases in patients taking antiepileptic drugs, patients treated with antiepileptic drugs should be monitored for suicidal impulses or behavior, onset or worsening of depression, and abnormal changes in mood and behavior.
(2) Epilepsy and many other diseases for which anti-epileptic drugs are prescribed are themselves associated with increased risk of morbidity and death, as well as suicidal impulses and suicidal behavior during the treatment period. Therefore, when prescribing antiepileptic drugs, prescribers consider whether there is a relationship between suicidal impulses or behavior during the patient's treatment period and the disease to be treated, as well as the effectiveness of the drug.

2. Do not administer to the following patients
1) Patients who are hypersensitive to pregabalin or the ingredients of this drug
2) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

3. Administer with caution to the following patients:
1) Diabetic patients: Diabetic patients who have recently gained weight due to administration of pregabalin may need to adjust the dose of their hypoglycemic agent.
2) Hypersensitivity reactions, including angioedema, have been reported in post-marketing experience. If symptoms of angioedema such as facial, perioral, and upper respiratory edema appear, pregabalin should be discontinued immediately.
3) Elderly: Administration of pregabalin has been associated with dizziness and drowsiness, which may increase the frequency of accidental injuries in elderly patients. Loss of consciousness, confusion, and mental disorders have been reported in post-marketing surveillance. Therefore, patients should be reminded to exercise caution until they become familiar with the potential effects of this drug.
4) In post-marketing experience, temporary blurred vision and other changes in vision were reported in patients administered pregabalin. These symptoms may disappear or improve after discontinuation of pregabalin.
5) There is insufficient data on the experience of controlling seizures by administering pregabalin as an adjuvant and then discontinuing the concomitant antiepileptic drug to administer pregabalin as monotherapy.
6) After discontinuation of pregabalin treatment for a short or long period of time, withdrawal symptoms such as insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, depression, suicidal thoughts, pain, seizures, hyperhidrosis, and dizziness were observed in some patients.
7) Pregabalin is not known to act on receptors related to drugs of abuse. However, cases of misuse, abuse, and dependence have been reported in post-marketing data. As with all other CNS-active drugs, patients' history of drug abuse and/or psychiatric disorders should be carefully reviewed. Patients with a history of drug abuse may be at higher risk for abuse of pregabalin and should be particularly cautious when administering this drug. Patients receiving pregabalin should be observed for signs and symptoms of drug misuse, abuse, or dependence (e.g., development of tolerance, increased dosage, drug-seeking behavior).
8) Although the effect of drug discontinuation on renal dysfunction has not been systematically studied, there have been reports that renal function improved after discontinuation or dose reduction of pregabalin.
9) Although a causal relationship has not been confirmed between pregabalin exposure and congestive heart failure, congestive heart failure has been reported in some patients administered pregabalin in post-marketing surveillance. Short-term trials in patients without clinically significant cardiac or peripheral vascular disease showed no clear association between peripheral edema and cardiovascular complications such as hypertension or congestive heart failure. Because there are insufficient data on patients with severe congestive heart failure, it should be administered cautiously to these patients.
10) Be careful when administering this drug and opioid analgesics together as there is a risk of central nervous system depression. In an observational study of opioid analgesic users, patients receiving this drug in combination with an opioid analgesic had a higher risk of opioid-related death than those receiving an opioid analgesic alone (adjusted odds ratio (aOR): 1.68, 95% confidence interval: 1.19-2.36).
11) Severe respiratory depression has been reported with the use of this drug. People with reduced respiratory function, respiratory or neurological disease, kidney impairment, and older adults may be at higher risk of experiencing these serious adverse reactions. Dosage adjustments may be necessary in these patients.
12) Women of childbearing potential/contraception: If this drug is administered in the first trimester of pregnancy (within the first 3 months of pregnancy), major congenital malformations may occur in the fetus. This drug should not be administered to pregnant women unless the benefit to the mother clearly outweighs the potential risk to the fetus. When administering to women of childbearing potential, effective contraception must be used (see 7. Administration to pregnant and lactating women).

4. Adverse reactions
1) In the clinical program for this drug, the drug was administered to more than 12,000 patients, of which more than 7,000 patients participated in double-blind, placebo-controlled clinical trials. The most commonly reported adverse reactions were dizziness and drowsiness, and adverse reactions were generally mild to moderate in severity. In all controlled clinical trials, discontinuation of treatment due to adverse reactions occurred in 14% of patients receiving pregabalin and 5% of patients receiving placebo. The most common adverse reactions that led to discontinuation of treatment were dizziness and drowsiness. Adverse reactions selected as drug-related in the pooled analysis of clinical trials are listed according to organ system (SOC) and frequency in the table below. The frequency of these terms was based on all causal adverse events in the clinical trial data.

-Very common: ≥1/10
-Common: ≥1/100, <1/10
-Uncommon: ≥1/1000, <1/100
-Rare: <1/1000

Adverse reactions listed in the table below may occur in association with underlying diseases and/or concomitant medications.

[Table 2] Adverse reactions from clinical trial experience: refer to manual

2) Adverse reactions observed in post-marketing surveillance
(1) Overseas post-marketing experience
- Immune system: Uncommon: hypersensitivity, rare: angioedema, allergic reactions.
- Nervous system: Very common: headache, uncommon: loss of consciousness, mental disorders.
- Eyes: Rare: Keratitis.
- Cardiac: Rare: Congestive heart failure.
- Respiratory system: Rare: pulmonary edema.
- Digestive system: Common: nausea, diarrhea, rare: tongue edema.
- Skin and subcutaneous tissue: Uncommon: facial edema, pruritus, Rare: Stevens-Jones syndrome, toxic epidermal necrolysis.
- Kidney and urinary system: Rare: urinary retention.
- Reproductive system and breasts: Rare: Gynecomastia.
- Systemic abnormalities and administration site: Uncommon: Malaise
Unexplained shock, anaphylaxis-like symptoms, cutaneous mucous membrane syndrome (Stevens-Jones syndrome), and erythema multiforme may occur, so observe carefully. If abnormalities are identified, stop administration and take appropriate measures.
(2) Domestic post-marketing survey results
As a result of a use result survey conducted on 3,926 people over 6 years for re-examination in Korea, the adverse event rate regardless of causal relationship was reported to be 4.96% (195 people/3,926 people, 262 cases), and among these, the adverse drug reaction rate for which a causal relationship with this drug could not be ruled out was 4.30% (169 people/3,926 people, 226 cases). Drowsiness was the most common at 1.73% (68 people/3,926 people, 68 cases), dizziness at 1.71% (67 people/3,926 people, 67 cases), dry mouth at 0.53% (21 people/3,926 people, 21 cases), edema at 0.31% (12 people/3,926 people, 12 cases), and vertigo. 0.18% (7 people/3,926 people, 7 cases), vomiting and peripheral edema each at 0.13% (5 people/3,926 people, 5 cases), tremors and worsening convulsions at 0.10% (4 people/3,926 people, 4 cases) each, and other adverse drug reactions reported at less than 0.1% are classified by institution as follows.
- Whole body: fatigue, weakness, gait abnormality
- Mental system: decreased libido, sleep disorders, insomnia
- Nervous system: ataxia, speech disorder, sensory abnormality, memory disorder, attention disorder
- Digestive system: constipation, gastrointestinal disorders, bloody stool
- Kidney and urinary system: increased BUN, urinary incontinence, difficulty urinating
- Reproductive system Breasts: erectile dysfunction
- Metabolism and nutrition: low blood sugar, increased appetite
- Eyes: Double vision, blurred vision
- Ears and appendages: Tinnitus
- Skin and subcutaneous tissue: facial edema, skin disease
- Test: Increased blood creatinine, weight gain
Among these, unexpected adverse drug reactions that did not appear in pre-market clinical trials were reported as worsening convulsions at 0.10% (4 people/3,926 people, 4 cases), gastrointestinal disorders, tinnitus, sleep disorders, skin diseases, increased BUN, and bloody stool at 0.03% (1 person/3,926 people, 1 case).
Three serious adverse events (colon carcinoma, gastroenteritis, and pneumonia) were reported in two people regardless of causal relationship.
The incidence of adverse events in patients with renal impairment was reported to be as high as 15.71% (11 patients/70 patients, 14 cases), and among these, adverse drug reactions for which a causal relationship with this drug could not be ruled out were observed at 10.00% (7 patients/70 patients, 10 cases).
3) Patients treated with antiepileptic drugs show suicidal impulses or behavior, onset or worsening of depression, and abnormal changes in mood and behavior. An analysis of 199 placebo-controlled clinical trials (monotherapy and adjunctive therapy) using 11 different antiepileptic drugs showed that patients taking antiepileptic drugs had a risk of suicidal impulses or behavior that was approximately twice that of patients taking placebo. During the 12-week treatment period, the incidence of suicidal behavior or suicidal impulses was 0.43% in 27,864 antiepileptic drug-treated patients and 0.24% in 16,029 placebo-treated patients. This means that one out of every 530 patients treated had suicidal thoughts or behavior. There were four suicides in patients treated with this drug and no suicides in patients treated with placebo. However, the number of suicides is too small to conclude a link between this drug and suicide. The increased risk of suicidal thoughts or behavior due to taking antiepileptic drugs was observed in the first week of starting drug treatment and continued throughout the treatment period. Most clinical trials could not exceed 24 weeks and could not assess the risk of suicidal thoughts or behavior beyond 24 weeks. The risk of suicidal ideation or behavior was consistent across the 11 antiepileptic drugs analyzed. The increased risk for antiepileptic drugs with diverse mechanisms of action and range of use indicates that there is a risk for all antiepileptic drugs used for any efficacy. The risk did not differ depending on age (5-100 years) in the clinical trials analyzed.
4) As a result of analyzing domestic voluntary adverse event reporting data (1989-2014), the adverse events reported in statistically significantly higher numbers compared to adverse events occurring in other pharmaceutical products for which adverse events were reported were as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
- Mental world: delirium
5) As a result of analysis and evaluation of clue information based on domestic post-marketing adverse event reporting data (1989-June 2015), the newly confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
- Nervous system: paralysis (facial paralysis)

5. General precautions
1) Inform patients and their guardians that antiepileptic drugs may increase the risk of developing or worsening signs and symptoms of depression, abnormal changes in mood and behavior, suicidal impulses, suicidal behavior, or self-harm, so that if the patient develops such symptoms or behavior, they can immediately report it to a medical professional.
2) The effectiveness of this drug was proven in clinical trials targeting patients with diabetic peripheral neuropathy and postherpetic neuralgia. Efficacy in other neuropathic pain conditions has not been evaluated.
3) Effects on driving and using machines: This drug may cause dizziness and drowsiness. Patients should be advised not to drive, operate complex machinery, or engage in any potentially hazardous activity while taking this medication until it is known whether this medication affects these activities.
4) Severe skin adverse reactions (SCAR), which can be life-threatening or fatal, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been rarely reported overseas in relation to treatment with this drug. When prescribing, the patient should be informed of signs and symptoms and skin reactions should be closely monitored. If symptoms and signs suggestive of these skin reactions occur, this medication should be discontinued immediately and alternative treatment options should be considered.

6. Interaction
1) Pregabalin is hardly metabolized in the human body and is mainly excreted in urine as an unchanged form (less than 2% of the dose is reabsorbed in urine as a metabolite). It does not inhibit drug metabolism in vitro, and does not bind to plasma proteins, so it does not appear to cause or be affected by pharmacokinetic interactions.
2) Therefore, in in vivo tests, no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone, and ethanol. A population pharmacokinetic analysis showed that oral hypoglycemic agents, diuretics, insulin, phenobarbital, tiagabine, and topiramate did not have a clinically significant effect on the clearance of pregabalin.
3) Co-administration of pregabalin and oral contraceptives such as norethisterone and/or ethinyl estradiol did not affect the steady-state pharmacokinetics of each other.
4) In controlled clinical trials, multiple co-administration of pregabalin, oxycodone, lorazepam, and ethanol did not have a clinically significant effect on respiration. Pregabalin affects the decline in cognitive and motor function caused by oxycodone. Pregabalin may potentiate the effects of ethanol and lorazepam.
5) In post-marketing surveillance, respiratory failure and coma have been reported in patients taking pregabalin and other central nervous system depressants.
6) In post-marketing surveillance, cases related to decreased lower digestive system function (e.g., ileus, asthenic ileus, constipation) have been reported when administered in combination with drugs containing constipation-inducing ingredients such as opioid analgesics.
7) Studies on pharmacodynamic interactions have not been conducted in elderly volunteers.

7. Administration to pregnant and lactating women
1) Pregnant women: Appropriate data on the administration of pregabalin to pregnant women are limited.
We estimated the risk of major congenital malformations, adverse birth outcomes, and abnormal postnatal neurodevelopmental outcomes following pregabalin exposure from an observational study of more than 2,700 cases of pregabalin exposure during pregnancy (data routinely collected from administrative and medical records in Denmark, Finland, Norway, and Sweden).
· Major congenital malformations: In a standard meta-analysis of the group exposed to pregabalin compared to the group not exposed to antiepileptic drugs in the first trimester (within the first 3 months of pregnancy), the adjusted prevalence rates (aPRs) and 95% confidence interval (CI) were 1.13 (0.97-1.33), and no statistically significant increase was observed.
· Birth outcomes: In a standard meta-analysis of the pregabalin-exposed group compared to the anti-epileptic drug-unexposed group, low birth weight, premature birth, and low Apgar score were observed, except for stillbirth (aPRs=1.72, 95 % CI 1.02-2.91) and small-for-gestational-age infants (SGA, aPRs=1.21, 95 % CI 1.01-1.44). and the risk of microcephaly did not show a statistically significant increase.
· Postnatal neurodevelopmental outcomes: In a standard meta-analysis of the pregabalin-exposed group compared to the antiepileptic drug-unexposed group, the adjusted hazard ratio (aHR) and 95% confidence interval (CI) for attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and intellectual disability (ID) were 1.32 (1.04-1.67), 1.00 (0.68-1.47), respectively. It was 1.03 (0.80-1.32).
Some significant results (stillbirth, SGA, ADHD) should be interpreted cautiously considering insufficient numbers and confounding factors.

Tests on animals showed reproductive toxicity. This drug should not be administered to pregnant women, except in cases where the benefit to the mother outweighs the risk to the fetus. When administering to women of childbearing potential, effective contraception must be used (see 3. Administration with caution to the following patients).
2) Nursing mothers: Pregabalin is transferred into the breast milk of nursing mothers. Because the safety of pregabalin in infants has not been established, breastfeeding is not recommended while taking pregabalin. A decision should be made whether to discontinue breastfeeding or pregabalin administration, considering the benefit of breastfeeding for the infant and the benefit of treatment for the mother.

8. Administration to the elderly (age 65 or older)
In elderly people, the clearance of pregabalin tends to decrease with age. A decrease in oral clearance of pregabalin is associated with a decrease in creatinine clearance with advancing age. In patients whose renal function declines with age, dosage adjustment of this drug may be necessary.

9. Treatment in case of overdose
In post-marketing surveillance, the most common adverse reactions observed with pregabalin overdose were affective disorders, somnolence, confusion, depression, agitation, and restlessness. Seizures have also been reported. In case of pregabalin overdose, general supportive measures and, if necessary, hemodialysis are required.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

11. Pharmaceutical equivalence test information
A. The test drug Pregabalin Capsule 150 mg (KyungDong Pharm Co., Ltd.) and the reference drug Lyrica Capsule 150 mg (Pregabalin) (Pfizer Korea Pharmaceutical Co., Ltd.) were administered orally once, 1 capsule each, to healthy adults in a 2×2 cross-over study. As a result, blood pregabalin was measured in 30 people on an empty stomach. When the comparative evaluation item values (AUCt, Cmax) were log-transformed and statistically processed, The 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.

- Table: Refer to manual -

B. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, the test drug Pregabalin Capsule 75 mg (KyungDong Pharm Co., Ltd.) submitted comparative dissolution test data with the reference drug Pregabalin Capsule 150 mg (KyungDong Pharm Co., Ltd.), and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.

12. Others
1) Preclinical safety data
(1) Results of pharmacological safety tests on animals showed that pregabalin was well tolerated at clinically relevant doses. In repeated dose toxicity tests conducted on rats and monkeys, effects on the central nervous system such as decreased activity, increased activity, and ataxia were observed. An increased incidence of retinal atrophy was observed in aged albino rats exposed over a long period of time to doses equivalent to more than 5 times the average human exposure at the highest clinically recommended dose.
(2) Pregabalin did not cause fetal toxicity in mice, rats, or rabbits. Fetal toxicity in rats and rabbits occurred only when exposed to high doses significantly higher than the human dose. In pre- and postnatal toxicity tests, pregabalin showed developmental toxicity in rat fetuses exposed to doses more than twice the highest recommended human dose.
(3) Pregabalin did not show genotoxicity based on the results of in vitro and in vivo tests.
(4) Pregabalin was subjected to a 2-year carcinogenicity test in rats and mice. No tumors were observed in rats exposed to a dose equivalent to 24 times the average human exposure at the highest recommended human dose of 600 mg per day. Additionally, no increase in tumor frequency was observed in mice exposed to doses similar to the average human exposure dose. However, an increase in the frequency of hemangiosarcoma was observed at high doses of exposure. The mechanism of pregabalin-induced tumorigenesis in mice was a non-genetic mechanism involving platelet changes and endothelial cell proliferation. Based on short-term and limited long-term clinical data, platelet changes were not observed in rats and humans. Therefore, there is no evidence of risk in humans associated with it.
(5) The type of toxicity observed in juvenile rats was not qualitatively different from that observed in adult rats, but fetal rats were more sensitive. At therapeutic doses of exposure, there was evidence of central nervous system clinical signs, including increased activity, bruxism, and slight changes in growth (temporary inhibition of weight gain). Effects on the estrous cycle were observed at 5 times the human therapeutic exposure. Neurobehavioral/cognitive effects were observed in rat fetuses exposed for 1-2 weeks (auditory startle response)/5 weeks (learning/memory) at doses >2 times the human therapeutic exposure. A decrease in auditory startle response was observed in young rats exposed for 1-2 weeks to doses more than twice the human therapeutic exposure. After 9 weeks of exposure, this effect was no longer observed.


5. How to save
Airtight container, stored at 15~30℃

6. Packaging unit
30 capsules/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 6items

No.Product NameDetailsDate of ChangeDownload
6Neucapen cap.75mgPrecautions for use2025.03.18PDFNew Capen Capsule 75 mg_201804826_Change in precautions for use (draft).pdf
5Neucapen cap.75mgPrecautions for use2024.08.125. New capen capsule 75mg, 150mg unified adjustment (draft) and addition of change comparison table.pdfFile under review
4Neucapen cap.75mgPrecautions for use2023.02.09PDFPregabalin single agent (oral) change order contents (four weeks)_including change comparison table.pdf
3Neucapen cap.75mgNewcapen Capsule 75mg (Precautions for use)2022.11.19Change order_Precautions for use_New capen capsule 75 mg (including change comparison table).pdfFile under review
2Neucapen cap.75mgPrecautions for use2021.06.09HWPContents of permit change order (including change comparison table).hwp
1Neucapen cap.75mgPrecautions for use2021.03.16HWPPermission change order (draft) and change comparison table_Pregabalin single drug (oral drug).hwp